Yearly Archives: 2016

Grupo Aeroportuario Del Pacifico (PAC-NYSE, $96.93) and Grupo Aeroportuario Del Sureste (ASR-NYSE, $152.38) Price Targets Increased.

PAC: New Price Target $115 ASR: New Price Target $175

Posted in Portfolio Model Subscription

Grupo Aeroportuario Del Sureste (ASR-NYSE, $149.94) files 20-F.

http://www.sec.gov/Archives/edgar/data/1123452/000110465916111773/a16-8289_120f.htm The recent 20-F filing indicates that construction of the Cancun International Terminal 4 is now underway. “The construction of the Terminal 4 has commenced, The new terminal is to be located to the west of the existing airport facilities,

Posted in Portfolio Model Subscription

Portfolio Return for Q1, 2016 of (-1.6%).

For the fiscal quarter ended March 31st, 2016, the Large Cap Model Growth Account was valued at $142.62 per share. When compared to the value at year end of $14.490 per share, this represents a loss in the quarter of

Posted in Portfolio Model Subscription

HNA Infrastructure (0357-hk, $8.99 HK). The Torrid Growth Rate Continues.

HNA Infrastructure reported the fiscal 2015 year end results. http://www.mlairport.com/autoportal/admin/upload/ReadAttach?uid=8a8181adss61c79017s1536976969ass7f71 For 2016, a 20% revenue increase produced a 31% increase in net after tax profits along with a 28.7% increase in EBITDA. EBITDA touched $99 million, which represents an EBITDA

Posted in Portfolio Model Subscription

Novo Nordisk (NVO-NYSE, $56.75). Victoza use Reduces Risk of Heart Attacks & Strokes

Those taking Victoza reported a statistically significant reduction in heart attack and stroke occurrence, in the largest study of its kind to date. http://www.investors.com/news/technology/novo-nordisk-diabetes-drug-cuts-deaths-from-heart-disease/?ven=YahooCP&src=AURLLED&ven=yahoo The test seems to clearly demonstrate superiority for Victoza over competing products produced by Merck and

Posted in Portfolio Model Subscription
Recent Comments